DDInter1042 DDInter1247
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Moxifloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Moxifloxacin {u} (Compound) binds {v} (Gene) TOP2A
Moxifloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Moxifloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Moxifloxacin {u} (Compound) causes {v} (Side Effect) Oedema
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomustine
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Denileukin diftitox
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium acetate
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Eribulin
Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Moxifloxacin (Compound) binds TOP2A (Gene)
Moxifloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Moxifloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Moxifloxacin (Compound) causes Oedema (Side Effect)
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Denileukin diftitox
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium acetate
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Moxifloxacin may lead to a major life threatening interaction when taken with Eribulin